Trial Information

Summary: First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy

The purpose of this study is to test an investigational drug, vinflunine (BMS-710485), in combination with gemcitabine in patients with Transitional Cell Carcinoma who cannot be treated with cisplatin. This study will help to determine whether vinflunine in combination with gemcitabine will extend the time period until further growth of the tumor more then gemcitabine alone.

Inclusion Criteria

• Clinical diagnosis of transitional cell carcinoma of the urothelium that is locally advanced or metastatic
• Ineligible for cisplatin-based therapy because of at least one of the following two medical conditions:
  • Calculated creatinine clearance = 60 mL/min OR
  • New York Heart Association Classification Stage II-IV Congestive Heart Failure
• Measurable disease documented by imaging with at least one uni-dimensional lesion
• Adequate performance status (ECOG 0, 1, or 2)
• Men or women = 18 years of age

Exclusion Criteria

• Patients in whom radiation or surgery is indicated
• Current neuropathy = CTCAE grade 3
• Prior radiation to = 30% of bone marrow
• Inadequate renal function: serum creatinine clearance = 20 mL/min
• Prior allergy to any vinca alkaloid

For more information,

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:30:41 AM